LDL-C Management: From Risk Assessment to Combination Therapies

A primary challenge in cardiovascular risk reduction is the accurate identification of individuals who will benefit most from intensive lipid-lowering interventions. Traditional risk calculators, while useful, may underestimate risk in certain populations, such as those with familial hypercholesterolaemia, chronic kidney disease, or established atherosclerotic cardiovascular disease (ASCVD). Consequently, a more nuanced approach to risk assessment is advocated, incorporating factors beyond standard Framingham or SCORE models. This includes evaluating lipoprotein(a) levels, particularly in patients with a family history of premature ASCVD or recurrent events despite optimal LDL-C control. Coronary artery calcium (CAC) scoring also provides incremental prognostic value, reclassifying a substantial proportion of intermediate-risk individuals into higher-risk categories, thereby justifying more aggressive therapeutic strategies.

Optimising Therapeutic Strategies

The therapeutic landscape for LDL-C reduction has expanded significantly beyond statin monotherapy. While high-intensity statins remain the foundational treatment, many patients, particularly those in very high-risk categories, do not achieve their target LDL-C levels with statins alone. This necessitates the sequential or concomitant addition of non-statin therapies. Ezetimibe, an intestinal cholesterol absorption inhibitor, provides an average additional LDL-C reduction of 15% to 20% when added to statin therapy. Its mechanism of action is complementary to statins, which primarily inhibit endogenous cholesterol synthesis. The combination of a statin and ezetimibe is generally well-tolerated and has demonstrated a reduction in cardiovascular events in large-scale trials.

For patients requiring further LDL-C reduction, particularly those with established ASCVD, familial hypercholesterolaemia, or very high-risk diabetes, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a potent therapeutic option. These monoclonal antibodies, such as evolocumab and alirocumab, can lower LDL-C by an additional 50% to 60% when added to maximally tolerated statin and ezetimibe therapy. Clinical trials have consistently shown that PCSK9 inhibitors significantly reduce major adverse cardiovascular events (MACE) in high-risk populations, with relative risk reductions in the range of 15% to 20% over a median follow-up of 2 to 3 years. The safety profile of PCSK9 inhibitors has been favourable, with injection site reactions being the most common adverse event.

Emerging therapies, such as inclisiran, a small interfering RNA (siRNA) targeting PCSK9 mRNA, offer a different dosing regimen, administered subcutaneously twice yearly after an initial loading dose. This infrequent dosing schedule may improve adherence, a critical factor in long-term lipid management. Inclisiran has demonstrated sustained LDL-C reductions of approximately 50% in patients with ASCVD or familial hypercholesterolaemia. Bempedoic acid, an ATP citrate lyase inhibitor, provides an alternative for patients intolerant to statins or requiring additional LDL-C lowering, reducing LDL-C by approximately 18% to 28% as monotherapy or in combination with ezetimibe. These agents expand the armamentarium available to clinicians, allowing for more individualised and aggressive treatment strategies to meet stringent LDL-C targets.

The integration of these therapies into clinical practice requires a clear understanding of patient risk profiles and guideline recommendations. Current guidelines from bodies such as the European Society of Cardiology (ESC) advocate for an LDL-C target of less than 1.4 mmol/L (55 mg/dL) for very high-risk patients and less than 1.8 mmol/L (70 mg/dL) for high-risk patients. Achieving these targets often necessitates combination therapy, moving away from a stepwise approach to a more proactive, intensified strategy from the outset for appropriate patients. The focus is shifting towards achieving 'lower for longer' LDL-C levels to maximise cardiovascular benefit.

Despite the advancements, challenges remain. Adherence to long-term lipid-lowering therapy is a significant hurdle, with many patients discontinuing medications due to perceived side effects, cost, or lack of understanding regarding the chronic nature of their condition. Healthcare systems must address these barriers through patient education, shared decision-making, and accessible prescribing options. Furthermore, while the efficacy and safety of current combination therapies are well-established, ongoing research continues to explore novel targets and therapeutic modalities. Gene-editing technologies, for instance, hold promise for durable LDL-C reduction, potentially offering a one-time treatment for certain genetic dyslipidemias.

The economic implications of these advanced therapies also warrant consideration. While PCSK9 inhibitors and other newer agents are highly effective, their cost can be substantial, leading to access issues for some patients. Value-based assessments and negotiations are crucial to ensure these life-saving treatments are available to those who need them most. Ultimately, effective LDL-C management requires a holistic approach, integrating robust risk assessment, individualised therapeutic strategies, and continuous patient engagement, all within a supportive healthcare framework that balances clinical efficacy with economic realities.